Monthly Archives: October 2018

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic

By | Uncategorized | No Comments

Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.

Read More